Ishares Genomics Immunology Etf Probability Of Bankruptcy
| IDNA Etf | USD 23.66 0.36 1.55% |
IShares |
iShares Genomics Immunology ETF chance of distress Analysis
IShares Genomics' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current IShares Genomics Probability Of Bankruptcy | Less than 9% |
Most of IShares Genomics' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, iShares Genomics Immunology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of IShares Genomics probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting IShares Genomics odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of iShares Genomics Immunology financial health.
The market value of iShares Genomics Imm is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Genomics' value that differs from its market value or its book value, called intrinsic value, which is IShares Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Genomics' market value can be influenced by many factors that don't directly affect IShares Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, iShares Genomics Immunology has a Probability Of Bankruptcy of 9.0%. This is much higher than that of the iShares family and significantly higher than that of the Health category. The probability of bankruptcy for all United States etfs is notably lower than that of the firm.
IShares Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses IShares Genomics' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the etfs which would be a good addition to a portfolio. Peer analysis of IShares Genomics could also be used in its relative valuation, which is a method of valuing IShares Genomics by comparing valuation metrics of similar companies.IShares Genomics is currently under evaluation in probability of bankruptcy as compared to similar ETFs.
IShares Fundamentals
| Number Of Employees | 403 | |||
| Beta | 1.15 | |||
| Total Asset | 170.27 M | |||
| One Year Return | 19.20 % | |||
| Three Year Return | (19.70) % | |||
| Five Year Return | (2.40) % | |||
| Net Asset | 170.27 M | |||
| Last Dividend Paid | 0.24 | |||
| Equity Positions Weight | 99.56 % |
About IShares Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze iShares Genomics Immunology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of IShares Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of iShares Genomics Immunology based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether iShares Genomics Imm offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of IShares Genomics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ishares Genomics Immunology Etf. Outlined below are crucial reports that will aid in making a well-informed decision on Ishares Genomics Immunology Etf:Check out IShares Genomics Piotroski F Score and IShares Genomics Altman Z Score analysis. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
The market value of iShares Genomics Imm is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Genomics' value that differs from its market value or its book value, called intrinsic value, which is IShares Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Genomics' market value can be influenced by many factors that don't directly affect IShares Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.